Combined IFN-α and 5-FU treatment as a postoperative adjuvant following surgery for hepatocellular carcinoma with portal venous tumor thrombus

Experimental and Therapeutic Medicine

Volumn 5, Issue 1, 2013, Pages 3-10

  Nagano, Hiroaki ^a   Kobayashi, Shogo ^a   Marubashi, Shigeru ^a   Wada, Hiroshi ^a   Eguchi, Hidetoshi ^a   Tanemura, Masahiro ^a   Tomimaru, Yoshito ^a   Umeshita, Koji ^a   Doki, Yuichiro ^a   Mori, Masaki ^a  

^a OSAKA UNIVERSITY   (Japan)

Author keywords

Chemotherapy; HCC; IFN; PVTT; Surgery

Indexed keywords

ALPHA INTERFERON; FLUOROURACIL; OIF; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DISEASE FREE SURVIVAL; DRUG EFFECT; FEMALE; FEVER; FOLLOW UP; HUMAN; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER FUNCTION; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PORTAL VENOUS TUMOR THROMBUS; POSTOPERATIVE CARE; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; QUALITY OF LIFE; SOCIAL LIFE; SURVIVAL RATE; THROMBOCYTOPENIA; TUMOR THROMBUS;

EID: 84869456686     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2012.736     Document Type: Article

References (45)

1. Arii S, Monden K, Niwano M, et al: Results of surgical treatment for recurrent hepatocellular carcinoma; comparison of outcome among patients with multicentric carcinogenesis, intrahepatic metastasis, and extrahepatic recurrence. J Hepatobiliary Pancreat Surg 5: 86-92, 1998.
2. Llovet JM, Ricci S, Mazzaferro V, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390, 2008.
3. Kudo M and Okanoue T: Management of hepatocellular carcinoma in Japan: consensus-based clinical practice manual proposed by the Japan Society of Hepatology. Oncology 72 (Suppl 1): S2-S15, 2007.
4. Chung YH, Song IH, Song BC, et al: Combined therapy consisting of intraarterial cisplatin infusion and systemic interferon-alpha for hepatocellular carcinoma patients with major portal vein thrombosis or distant metastasis. Cancer 88: 1986-1991, 2000.
5. Kaneko S, Urabe T and Kobayashi S: Combination chemotherapy for advanced hepatocellular carcinoma complicated by major portal vein thrombosis. Oncology 62 (Suppl 1): S69-S73, 2002.
6. Patt YZ, Hassan MM, Lozano RD, et al: Phase II trial of systemic continuous fuorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma. J Clin Oncol 21: 421-427, 2003.
7. Obi S, Yoshida H, Toune R, et al: Combination therapy of intra-arterial 5-fuorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion. Cancer 106: 1990-1997, 2006.
8. Uka K, Aikata H, Takaki S, et al: Similar effects of recombinant interferon-alpha-2b and natural interferon-alpha when combined with intra-arterial 5-fuorouracil for the treatment of advanced hepatocellular carcinoma. Liver Int 27: 1209-1216, 2007.
9. Sakon M, Nagano H, Dono K, et al: C o m b i n e d i n t r a a r t e r i a l 5 - f u o -rouracil and subcutaneous interferon-α therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. Cancer 94: 435-442, 2002.
10. Ota H, Nagano H, Sakon M, et al: Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fuorouracil; role of type 1 interferon receptor expression. Br J Cancer 93: 57-64, 2005.
11. Nagano H, Wada H, Kobayashi S, et al: Long-term outcome of combined subcutaneous interferon-α and intra-arterial 5-fuo-rouracil treatment for advanced hepatocellular carcinoma with major portal vein thrombosis. Oncology (In Press).
12. Eguchi H, Nagano H, Yamamoto H, et al: Augmentation of antitumor activity of 5-fuorouracil by interferon alpha is associated with up-regulation of p27Kip1 in human hepatocellular carcinoma cells. Clin Cancer Res 6: 2881-2890, 2000.
13. Yamamoto T, Nagano H, Sakon M, et al: Partial contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway to anti-tumor effects of interferon-alpha/5-fuorouracil against hepatocellular carcinoma. Clin Cancer Res 10: 7884-7895, 2004.
14. Kondo M, Nagano H, Wada H, et al: Combination of IFN-alpha and 5-fuorouracil induces apoptosis through IFN-alpha/beta receptor in human hepatocellular carcinoma cells. Clin Cancer Res 11: 1277-1286, 2005.
15. Nakamura M, Nagano H, Sakon M, et al: Role of the Fas/FasL pathway in combination therapy with interferon-alpha and fuo-rouracil against hepatocellular carcinoma in vitro. J Hepatol 46: 77-88, 2007.
16. Noda T, Nagano H, Takemasa I, et al: Activation of Wnt/ beta-catenin signalling pathway induces chemoresistance to interferon-alpha/5-fuorouracil combination therapy for hepato-cellular carcinoma. Br J Cancer 100: 1647-1658, 2009.
17. Wada H, Nagano H, Yamamoto H, et al: Combination of interferon-alpha and 5-fluorouracil inhibits endothelial cell growth directly and by regulation of angiogenic factors released by tumor cells. BMC Cancer 9: 361-372, 2009.
18. Tomimaru Y, Eguchi H, Wada H, et al: Insulin-like growth factor-binding protein 7 alters the aensitivity to interferon-based anticancer therapy in hepatocellular carcinoma cells. Br J Cancer 102: 1483-1490, 2010.
19. Tomimaru Y, Eguchi H, Nagano H, et al: MicroRNA-21 induces resistance to the anti-tumor effect of interferon-α/5-fuorouracil in hepatocellular carcinoma cells. Br J Cancer 103: 1617-1626, 2010.
20. Nagano H, Sakon M, Eguchi H, et al: Hepatic resection followed by IFN-alpha and 5-FU for advanced hepatocellular carcinoma with tumor thrombus in the major portal branch. Hepatogastroenterology 54: 172-179, 2007.
21. Nagano H, Miyamoto A, Wada H, et al: Interferon-α and 5-fuorouracil combination therapy following palliative hepatic resection in patients with advanced hepatocellular carcinoma, portal venous tumor thrombus in the major trunk and multiple nodules. Cancer 110: 2493-2501, 2007.
22. The General Rules for the Clinical and Pathological Study of Primary Liver Cancer. 5th edition, Liver Cancer Study Group of Japan, 2008.
23. Oken MM, Creech RH, Tormey DC, et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5: 649-655, 1982.
24. Kaplan EL and Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958.
25. Ikai I, Arii S, Ichida T, et al: Report of the 16th follow-up survey of primary liver cancer. The Liver Cancer Study Group of Japan. Hepatol Res 32: 163-172, 2005.
26. Yamakado K, Tanaka N, Nakatsuka A, et al: Clinical effcacy of portal vein stent placement in patients with hepatocellular carcinoma invading the main portal vein. J Hepatol 30: 660-668, 1999.
27. Cancer of the Liver Italian Program (CLIP) investigators: A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology 28: 751-755, 1998.
28. Asahara T, Itamoto T, Katayama K, et al: Hepatic resection with tumor thrombectomy for hepatocellular carcinoma with tumor thrombi in the major vasculature. Hepatogastroenterology 46: 1862-1869, 1999.
29. Ohkubo T, Yamamoto J, Sugawara Y, et al: Surgical results for hepatocellular carcinoma with macroscopic portal vein thrombosis. J Am Coll Surg 191: 657-660, 2000.
30. Furuse J, Iwasaki M, Yoshino M, et al: Hepatocellular carcinoma with portal vein tumor thrombus: embolization of arterioportal shunts. Radiology 204: 787-790, 1997.
31. Lee HS, Kim JS, Choi IJ, et al: The safety and effcacy of trans-catheter arterial chemoembolization in the treatment of patients with hepatocellular carcinoma and main portal vein obstruction: a prospective controlled study. Cancer 79: 2087-2094, 1997.
32. Poon RT, Ng KK, Lam CM, et al: Learning curve for radio-frequency ablation of liver tumors: prospective analysis of initial 10 0 pat ients i n a ter ti a r y i nst it ut ion. Ann Su rg 239: 4 41- 4 49, 2 0 04.
33. Mazzaferro V, Regalia E, Doci R, et al: Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334: 693-700, 1996.
34. Poon RT, Fan ST, Ng IO and Wong J: Prognosis after hepatic resection for stage I VA hepatocellular carcinoma: a need for reclassifcation. Ann Surg 237: 376-383, 2003.
35. Ikai I, Yamaoka Y, Yamamoto Y, et al: Surgical intervention for patients with stage IV-A hepatocellular carcinoma without lymph node metastasis proposal as a standard therapy. Ann Surg 227: 433-439, 1998.
36. Shi J, Lai ECH, Li N, et al: Surgical treatment for hepatocellular carcinoma with portal vein tumor thrombus. Ann Surg Oncol 17: 2073-2080, 2010.
37. Tazawa J, Maeda M, Sakai Y, et al: R a d i a t i o n t h e r a p y i n c o m b i n a t i o n with transcatheter arterial chemoembolization for hepatocellular carcinoma with extensive portal vein involvement. J Gastroenterol Hepatol 16: 660-665, 2001.
38. Ishikura S, Ogino T, Furuse J, et al: Radiotherapy after transcatheter arterial chemoembolization for patients with hepatocellular carcinoma and portal vein tumor thrombus. Am J Clin Oncol 25: 189-193, 2002.
39. Minagawa M, Makuuchi M, Takayama T and Ohtomo K: Selection criteria for hepatectomy in patients with hepatocellular carcinoma and portal vein tumor thrombus. Ann Surg 233: 379-384, 2001.
40. Peng BG, He Q, Li JP and Zhou F: Adjuvant transcatheter arterial chemoembolization improves effcacy of hepatectomy for patients with hepatocellular carcinoma and portal vein tumor thrombus. Am J Surg 198: 313-318, 2009.
41. Nakamura M, Nagano H, Marubashi S, et al: A pilot study of combination chemotherapy of S-1, a novel oral DPD inhibitor, and interferon-alpha for advanced hepatocellular carcinoma with extrahepatic metastasis. Cancer 112: 1765-1771, 2008.
42. Llovet JM and Bruix J: Molecular targeted therapies in hepato-cellular carcinoma. Hepatology 48: 1312-1327, 2008.
43. Yang ZF, Poon RT, Liu Y, et al: High doses of tyrosine kinase inhibitor PTK787 enhance the effcacy of ischemic hypoxia for the treatment of hepatocellular carcinoma: dual effects on cancer cell and angiogenesis. Mol Cancer Ther 5: 2261-2270, 2006.
44. Zhu AX, Sahani DV, Duda DG, et al: Effcacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol 27: 3027-3035, 2009.
45. Murakami M, Kobayashi S, Marubashi S, et al: Tyrosine kinase inhibitor PTK/ZK enhances the anti-tumor effects of interferon-α/5-fuorouracil therapy for hepatocellular carcinoma cells. Ann Surg Oncol 18: 589-596, 2011.